DPP-4 Class Labeling On Heart Failure May Hinge On Merck Study
Executive Summary
AstraZeneca’s mechanistic study on saxagliptin, FDA’s Mini-Sentinel examination, and the soon-to-be-released TECOS cardiovascular outcomes study of Merck’s sitagliptin could all help clarify whether a DPP-4 inhibitor class effect exists.